1 – 19 of 19
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
(
- Contribution to journal › Article
-
Mark
Nuclear expression of pSTAT3Tyr705 and pSTAT3Ser727 in the stromal compartment of localized hormone-naïve prostate cancer
(
- Contribution to journal › Article
- 2021
-
Mark
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
(
- Contribution to journal › Article
- 2020
-
Mark
STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population
(
- Contribution to journal › Article
-
Mark
Cytokines and Janus kinase/signal transducer and activator of transcription signaling in prostate cancer : overview and therapeutic opportunities
(
- Contribution to journal › Scientific review
- 2019
-
Mark
Expression of tSTAT3, pSTAT3
727
, and pSTAT3
705
in the epithelial cells of hormone-naïve prostate cancer
(
- Contribution to journal › Article
-
Mark
The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors
(
- Contribution to journal › Article
- 2017
-
Mark
Expression of STAT3 in Prostate Cancer Metastases
(
- Contribution to journal › Article
-
Mark
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model
(
- Contribution to journal › Article
- 2016
-
Mark
The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
N-Conjugate prodrugs of galiellalactone
(
- Contribution to journal › Article
-
Mark
Preclinical Characterization of 3β-(N-Acetyl l -cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
(
- Contribution to journal › Article
- 2015
-
Mark
Therapeutic Targeting of Nuclear Gamma-Tubulin in RB1-negative Tumors.
(
- Contribution to journal › Article
- 2014
-
Mark
The fungal metabolite galiellalactone interferes with the nuclear import of NF-κB and inhibits HIV-1 replication.
(
- Contribution to journal › Article
-
Mark
Galiellalactone is a Direct Inhibitor of STAT3 in Prostate Cancer Cells.
(
- Contribution to journal › Article
- 2011
-
Mark
Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells.
(
- Contribution to journal › Article
- 2010
-
Mark
Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer
(
- Contribution to journal › Scientific review
- 2008
-
Mark
Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
(
- Contribution to journal › Article
- 2007
-
Mark
A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue.
(
- Contribution to journal › Article